M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

Phase 2

Active, not recruiting

Conditions: Invasive Breast Carcinoma
Bilateral Breast Carcinoma
HER2/Neu Negative

Interventions: Other: Best Practice
Drug: Ixabepilone

First Posted Date: 2009-04-07

Last Posted Date: 2024-12-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT00877500

Locations: 🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸
Advocate Christ Medical Center, Oak Lawn, Illinois, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients

Completed

Conditions: Brain Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2009-04-06

Last Posted Date: 2015-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00876499

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: BMTP-11

First Posted Date: 2009-03-31

Last Posted Date: 2015-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00872157

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer
Brain Cancer

Interventions: Drug: Tarceva (Erlotinib hydrochloride)
Radiation: Radiation Therapy

First Posted Date: 2009-03-30

Last Posted Date: 2021-09-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT00871923

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States

FTS Study in Patients With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Myelodysplastic Syndrome
Leukemia

Interventions: Drug: FTS

First Posted Date: 2009-03-23

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00867230

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide

Phase 2

Completed

Conditions: Lung Cancer
Gastrointestinal Disease
Esophageal Cancer

Interventions: Procedure: Breathing Test
Behavioral: Respiratory Symptoms Questionnaire
Procedure: Pet Scan

First Posted Date: 2009-03-23

Last Posted Date: 2014-08-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 163

Registration Number: NCT00867477

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation

Phase 1

Withdrawn

Conditions: Chronic Myelogenous Leukemia

Interventions: Biological: PR1-primed lymphocyte (PR1-CTL) Infusion

First Posted Date: 2009-03-20

Last Posted Date: 2014-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00866346

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Lymphoblastic Lymphoma
Lymphoblastic Leukemia

Interventions: Drug: Daunorubicin
Drug: Vincristine
Drug: PEG-asparaginase
Drug: Intrathecal Methotrexate
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Doxorubicin
Drug: Thioguanine

First Posted Date: 2009-03-20

Last Posted Date: 2019-09-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00866749

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cue Reactivity in Virtual Reality: The Role of Context

Terminated

Conditions: Smoking

Interventions: Other: Breath Sample
Other: Saliva Sample
Behavioral: Questionnaire
Behavioral: View Virtual Reality Scenes

First Posted Date: 2009-03-17

Last Posted Date: 2012-06-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00862927

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Identification and Treatment of Depression

Completed

Conditions: Cancer

Interventions: Behavioral: Questionnaires & Interviews
Behavioral: Telephone Intervention

First Posted Date: 2009-03-17

Last Posted Date: 2019-05-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 134

Registration Number: NCT00863200

Locations: 🇺🇸
LBJ General Hospital, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy